Thiazolidinediones and progression of renal disease in patients with diabetes

Journal of Investigative Medicine

Volumn 54, Issue 2, 2006, Pages 56-61

  Goyal, Abhijeet ^a   Crook, Errol D ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

African American; Blood pressure; End stage renal disease; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CREATININE; INSULIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES CONTROL; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN TREATMENT; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RENAL PROTECTION; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

EID: 33644794187     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2005.05034     Document Type: Article

References (30)

1. USRDS: the United States Renal Data System. Am J Kidney Dis 2003;42(6 Suppl 5):1-230.
2. Crook ED, Patel SR. Diabetic nephropathy in African American patients. Curr Diab Rep 2004;4:455-61.
3. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committee Working Group. Am J Kidney Dis 2000;36:646-61.
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
5. Jones AB. Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond. Med Res Rev 2001;21:540-52.
6. Chilton R, Chiquette E. Thazolidinediones and cardiovascular disease. Curr Atherosclerosis Rep 2005;7:115-20.
7. Imano E, Kanda T, Nakatani Y, et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998;21:2135-9.
8. Fujii M, Takemura R, Yamaguchi M, et al. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 1997;46:981-3.
9. Buckingham RE, Al-Barazanji KA, Toseland CDN, et al. Peroxisome proliferator-activated receptor-[gamma] agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998;47:1326-34.
10. Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000;49:1022-32.
11. Baylis C, Atzpodien EA, Freshour G, Engels K. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003;307:854-60.
12. Guo B, Koya D, Isono M, et al. Peroxisome proliferator-activated receptor-[gamma] ligands inhibit TGF-[beta]1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004;53:200-8.
13. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003;17:7-12.
14. Nakamura T, Ushiyama C, Suzuki S, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001;18:308-13.
15. Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000;14:250-4.
16. Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005;18:227-34.
17. National Kidney Foundation K/DOQI Working Group. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39 Suppl 1:76-92.
18. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-61.
19. Guan Y, Zhang Y, Schneider A, et al. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol 2001;281:F1036-46.
20. Nicholas SB, Kawano Y, Wakino S, et al. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension 2001;37:722-7.
21. Asano T, Wakisaka M, Yoshinari M, et al. Peroxisome proliferator- activated receptor [gamma]1 (PPAR[gamma]1) expresses in rat mesangial cells and PPAR[gamma] agonists modulate its differentiation. Biochim Biophys Acta 2000;1497:148-54.
22. McCarthy KJ, Routh RE, Shaw W, et al. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000;58:2341-50.
23. Ogihara T, Raguki H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995;8:316-20.
24. Raji A, Seely W, Bekins SA, et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003;26:172-8.
25. Chiquette E. Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104.
26. Sarafidis PA, Lasaridis PA, Lasaridis AN, et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 2004;22:1769-77.
27. Bennett SM, Agrawal A, Elasha H, et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 2004;21:415-22.
28. Minamikawa J, Tanaka S, Yamachi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83:1818-20.
29. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004;53:1382-6.
30. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273-7.